Introduction {#s1}
============

Methamphetamine (METH) remains among the most widely abused substances worldwide, and its use represents a substantial public health burden ([@CIT0020]). Although cognitive and behavioral treatment strategies have been shown to produce positive clinical outcomes in the short term ([@CIT0014]), maintaining prolonged periods of abstinence is particularly challenging for METH-dependent individuals; an estimated 60% to 80% relapse within a year of treatment ([@CIT0013]; [@CIT0002]). Both clinical and laboratory findings have demonstrated that administration of a single, low dose of the previously abused drug (i.e., priming dose) can trigger intense cravings, which dramatically increases the vulnerability to relapse ([@CIT0012]; [@CIT0006]; [@CIT0001]). Therefore, therapeutic interventions that can mitigate the impact of drug reexposure might prove useful to clinicians treating patients with stimulant use disorders.

Recent drug development efforts for the treatment of stimulant abuse (i.e., cocaine, METH) have largely focused on small-molecule pharmacotherapies aimed at various CNS neurotransmitter systems. These pharmacodynamic approaches target specific receptors or transporters to either attenuate the positive reinforcing and rewarding effects of the drug or to dampen the negative reinforcing effects brought on by withdrawal from it. Until now, however, this strategy is yet to produce a clinically viable target. The limited efficacy of pharmacodynamic drug candidates can be attributed, in part, to off-target effects and compensatory plasticity associated with chronic engagement of a target signaling system. Intended drug effects may be further complicated by an abundance of genetic polymorphisms known to influence drug metabolism, absorption, and excretion, which likely contribute to the high variability in pharmacological treatment outcomes ([@CIT0004]). Consequently, there are currently no consensus treatments or FDA-approved pharmacotherapies for stimulant use disorders, including METH use disorder, leaving clinicians treating patients addicted to METH with few clinical tools ([@CIT0017]). Alternatively, agents that alter the pharmacokinetics of METH may offer a favorable therapeutic profile without disturbing endogenous neural dynamics ([@CIT0019]; [@CIT0009]). However, studies of the enzymes, antibodies, and vaccines primarily utilized for this manner of treatment have revealed significant limitations of all such strategies due to lack of specificity ([@CIT0023]), variation in antibody titer ([@CIT0024]), or high cost of production ([@CIT0019]).

Initially developed to accelerate recovery from anesthetic neuromuscular blockade, the calabadion family of acyclic cucurbit\[n\]uril "molecular containers" facilitate drug clearance through rapid recognition and encapsulation of target molecules ([@CIT0011]; [@CIT0007]). Host-guest complexes are subsequently excreted in urine ([@CIT0010]). In an initial screening of several molecular container compounds with a high affinity toward hydrophobic cations, calabadion-2 (Cal2) was identified as having high affinity and specificity for (~+~) METH in vitro. Subsequent experiments to clarify its in vivo efficacy demonstrated that i.v. administration of Cal2 was sufficient to prevent and reverse the motor stimulant effects of METH in rats ([@CIT0008]). Since molecular containers possess favorable aqueous solubility, display high biocompatibility ([@CIT0016]), and can be synthesized on a large scale ([@CIT0025]), these preliminary findings position the calabadion family of compounds as an intriguing candidate therapeutic for pharmacokinetic modulation of METH activity in vivo.

Since doses of stimulant drugs necessary to enhance locomotor activity may exceed those capable of exerting stimulus-effects underlying subjective craving, the present studies sought to empirically examine the effects of calabadion-2 on a drug-primed reinstatement procedure: a preclinical model with both face and predictive validity for therapeutics that decrease drug relapse in humans ([@CIT0001]). In these experiments, male rats trained to self-administer i.v. METH were tested in a multi-phase extinction-reinstatement protocol. After rats had undergone extinction training, they were administered a priming dose of METH that was preceded by either saline or Cal2 pretreatment to establish the capacity for Cal2 to prevent METH-induced drug-seeking behavior. Finally, the pharmacological specificity of Cal2 was examined in a series of reinstatement tests preceded by yohimbine (Yoh) injection.

Methods {#s2}
=======

Subjects {#s3}
--------

Male Long-Evans rats (n = 12; Charles River Laboratories, Wilmington, MA) weighing 225 to 250 g on arrival were individually housed in clear polycarbonate cages (29 × 25 × 29 cm). After 1 week of habituation to the vivarium, rats were implanted with chronic, indwelling catheters into the jugular vein as previously described ([@CIT0015]). Animals were given 1 week to recover before being transferred to operant conditioning chambers, where they remained for the duration of the study. Throughout the experiment rats were maintained on a reverse light/dark cycle (lights on: 8:00 [pm]{.smallcaps}--8:00 [am]{.smallcaps}) within a temperature-controlled environment and provided food and water ad libitum. Experimental procedures were approved by the Tufts University Institutional Animal Care and Use Committee and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, [@CIT0018]).

METH Self-Administration, Extinction, and Reinstatement {#s4}
-------------------------------------------------------

Self-administration sessions were carried out in the rats' home cages, which were custom-built clear acrylic chambers (30 × 30 × 24.5 cm) outfitted with a removable panel containing 2 retractable levers and 2 stimulus lights (Med Associates Inc.). Chambers were housed within sound- and light-attenuating enclosures prepared with a ventilation fan and house light. During self-administration sessions, a green stimulus light was illuminated to signal drug availability, and responses on the active lever were reinforced with 0.06 mg/kg METH infusion and concurrent illumination of a red stimulus light above the lever. Stimulus lights remained illuminated throughout the drug infusion and were extinguished during a subsequent post-infusion timeout period (30 seconds). Responses on the inactive lever or during the timeout were recorded but had no programmed consequence. Training sessions lasted for 5 hours or 30 infusions, whichever came first. After 2 consecutive days in which rats obtained at least 20 drug infusions under a simple fixed ratio (FR) schedule of 1 (each lever press was followed by an infusion), the schedule of reinforcement was gradually increased to a terminal schedule of FR3. In the event of \>5% loss of body weight between sessions, rats received 1 day off (no drug) in order to prevent excessive weight loss during initial training.

METH self-administration was maintained under an FR3 schedule of reinforcement for 10 days prior to extinction training. During extinction, responses on the active lever no longer produced any programmed consequences (i.e., no stimulus light presentation and no drug infusion). Each session lasted for 2 hours and was conducted twice daily, separated by 3 hours. Extinction criterion was met when active lever responses were reduced to \<20% of the responses emitted during the first extinction session, for 2 consecutive sessions.

For reinstatement tests, drug treatments (130 mg/kg calabadion-2 or saline \[Sal\]) were delivered i.v. 5 minutes before a priming injection of either METH (0.3 mg/kg, i.v.) or Yoh (1.0 mg/kg, i.v.) at the onset of the session. A higher dose of METH (3.0 mg/kg, i.v.) was further examined in a subset of rats (n = 4).

Reinstatement sessions were identical to the extinction procedure, where lever responses were recorded but had no programmed consequence. Drug test conditions were assigned in a counterbalanced manner to account for potential order effects and were as follows: Sal+METH, Cal2+METH, Sal+Yoh, Cal2+Yoh, Sal+Sal, and Cal2+Sal. All drug tests were conducted in the morning and were followed by a single session of METH self-administration (FR3; 2 hours). Between tests, extinction training was carried out such that the extinction criterion was met (\<20% of the responses recorded during the first extinction session) before each successive determination.

Drugs {#s5}
-----

d-Methamphetamine HCl (METH) was provided by the National Institute of Drug Abuse (Research Triangle Institute, Research Triangle Park, NC) and was dissolved in sterile 0.9% Sal for i.v. administration. Yoh was obtained from Sigma-Aldrich (Saint Louis, MO) and dissolved in sterile distilled water. Calabadion-2 was synthesized according to the previously published protocol ([@CIT0016]) in the laboratory of Dr Lyle Isaacs, at the University of Maryland (College Park, MD). Cal2 was suspended in sterile distilled water to a concentration of 130 mg/mL immediately prior to use. A dose of 130 mg/kg produced maximal effects without toxicity in previous behavioral studies in rats ([@CIT0008]) and was therefore selected for the present behavioral experiments.

Statistical Analysis {#s6}
--------------------

All statistical analyses were conducted using Prism version 7.0 (Graphpad Software Inc.). Active and inactive responses during extinction were assessed via paired *t* test, and behavior during reinstatement sessions was analyzed using factorial ANOVAs. All significant effects (*P \< .*05) were followed by post hoc analyses with Bonferroni corrections for multiple comparisons.

Results {#s7}
=======

Maintenance and Extinction {#s8}
--------------------------

Rats acquired METH self-administration under an FR3 schedule of reinforcement (i.e., ≥20 infusions per session) in 9.67 ± 1.50 days (mean ± SEM), and responding remained stable across 10 additional maintenance sessions ([Figure 1B](#F1){ref-type="fig"}). Extinction training significantly reduced responding on the drug-paired lever \[t~(11)~ = 5.233, *P \< .*001\], and all rats met extinction criteria after 12 sessions ([Figure 1C--D](#F1){ref-type="fig"}). Extinction, however, had no effect on inactive lever responding.

![Acquisition and extinction of methamphetamine (METH) self-administration. (A) Experimental timeline. (B) Mean (±SEM) number of active lever responses during maintenance of METH self-administration (0.06 mg/kg/infusion) and (C) extinction training. (D) Total responses recorded on the active and inactive levers during the first and last extinction session. \**P \< .*05; \*\**P \< .*01.](pyz070f0001){#F1}

Reinstatement {#s9}
-------------

A priming infusion of METH reinstated responding on the previously extinguished drug lever without altering responding on the inactive lever ([Figure 2A](#F2){ref-type="fig"}). The METH-induced drug-seeking was significantly attenuated by pretreatment with Cal2. Accordingly, main effects were found for both pretreatment (F~1,22~ = 53.00, *P \< .*001) and drug exposure (F~1,22~ = 36.94, *P \< .*001) condition, with a significant interaction between the two (F~2,22~ = 59.72, *P \< .*001). On the other hand, while Yoh produced a similar enhancement of drug-lever responding after extinction (F~1,12~ = 14.52, *P \< .*01), pretreatment with Cal2 was insufficient to prevent these effects (*P = .*773).

![Calabadion-2 specifically prevents methamphetamine (METH)-induced reinstatement. (A) Total responses on the previously active lever or inactive lever after a priming injection of saline (Sal), METH (0.3 mg/kg, i.v.; n = 12), or (B) yohimbine (Yoh; 1.0 mg/kg, i.v.; n = 8). Data are presented as mean (±SEM) of total responses during reinstatement tests. \#Difference from Sal+Sal control. \#*P \< .*05, \#\#*P \< .*01, \#\#\#*P \< .*001; \**P \< .*05; \*\**P \< .*01, \*\*\**P \< .*001.](pyz070f0002){#F2}

Discussion {#s10}
==========

The present studies are the first to evaluate an acyclic cucurbit\[n\]uril molecular container, calabadion-2, as a potential pharmacokinetic intervention for METH relapse-like behavior. Under these conditions, noncontingent administration of METH provoked a prominent burst of responding on the lever previously reinforced with METH. However, when administered prior to drug reexposure, Cal2 is sufficient to prevent METH-triggered drug seeking in rats. Although only examined in a subset of rats (data not shown), a 10-fold higher dose of METH (3.0 mg/kg), which was behaviorally disruptive alone, was sufficient to surmount Cal2 blockade to stimulate reinstatement responding. These findings are collectively consistent with the proposed mechanism that Cal2 can rapidly bind and sequester METH in the periphery to reduce its access to the brain, in turn preventing the stimulus properties of the drug ([@CIT0008]). Furthermore, the vigorous response output exhibited by rats that received Yoh after Cal2 pretreatment undermines the possibility of Cal2 effects being related to general motor impairment or that Cal2 might interact with other behavioral substrates of reinstatement such as associative, motivational, or inhibitory processes.

In addition to drug reexposure, it is important to consider that relapse can also be triggered by nondrug stimuli. Notably, both stress and exposure to drug-associated contexts and cues can stimulate drug craving humans and serve to reinstate METH seeking in animal models of relapse ([@CIT0022]; [@CIT0021]; [@CIT0001]). The finding that Cal2 failed to prevent the stress-related reinstatement of drug-seeking by Yoh administration, an alpha-2 adrenoceptor antagonist commonly used to induce stress-like behaviors ([@CIT0003]), therefore underlines the pharmacological specificity of Cal2 to selectively bind METH molecules. Although Cal2 cannot protect against environmental factors that might influence relapse vulnerability, it may, however, mitigate the intensity or duration of drug taking when a patient relapses back into METH use. Cal2 could provide a critical buffer against the reinforcing effects of METH in the event of resumed drug consumption.

Limitations {#s11}
-----------

The current studies provide a valuable proof of concept for calabadion-like molecular containers as a functional inhibitor of METH in a translationally relevant context. However, there are some practical limitations that constrain the efficacy of Cal2 in vivo. The excretion rate of calabadion-host complexes in urine indicates a functional half-life on the order of hours in rats ([@CIT0007]). The somewhat transient functionality of Cal2 is further complicated by the i.v. route of administration. Both the duration of drug action and route of administration are key determinants of compliance across a range of pharmacological therapeutics, where patients are increasingly likely to forego medication that requires frequent or impractical dosing regimens ([@CIT0005]). Importantly, the unpredictability of factors that might drive drug cravings or provoke relapse (i.e., environmental stress) demands consistent therapeutic compliance to be effective.

Further chemical optimization of Cal2 with regards to its binding affinity, selectivity, and half-life may overcome some of these practical limitations. Structural optimization that increases binding affinity includes the incorporation of a covalent capping group as a secondary binding site on one face of the molecule, a variation of the length of the glycoluril oligomer backbone to provide a larger hydrophobic driving force, and an increase in the ion-ion interactions between ammonium ion and solubilizing groups leading to improved electrostatic binding characteristics of the molecule.

In summary, we have demonstrated that Cal2 can selectively and effectively reduce relapse-like METH-seeking behavior in a preclinical model. Further research is required to determine whether molecular containers like Cal2 can provide a feasible pharmacokinetic approach to relapse prevention for METH-dependent individuals.
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